Educational article
Monobactams and aztreonam
Aztreonam is a monobactam acting mainly against aerobic Gram-negative bacteria. It interacts with proteins involved in cell-wall synthesis. Its spectrum differs from carbapenems, so it cannot be treated as a universal…
Overview
Aztreonam is a monobactam acting mainly against aerobic Gram-negative bacteria. It interacts with proteins involved in cell-wall synthesis. Its spectrum differs from carbapenems, so it cannot be treated as a universal agent against mixed flora.
Biology and practical meaning
Metallo-β-lactamases generally do not hydrolyse aztreonam, but the same bacterium may carry other enzymes that do. NDM detection alone therefore does not establish aztreonam susceptibility. Inhibitor combinations require assessment as specific agents under current standards.
Spectrum, exposure and AST
Spectrum describes the range of organisms an agent can act against; activity against a particular isolate is assessed separately. Access to the target, target changes, enzymes and efflux can alter activity. Agents in the same class are not completely interchangeable.
Pharmacokinetics describes distribution and elimination; pharmacodynamics links exposure to effect. Blood concentrations and exposure at the infection site can differ. A lower MIC number for a different antibiotic therefore does not establish superior clinical activity.
S, I and R are interpreted using a current standard for the organism–agent pair. Under EUCAST, I means susceptible with increased exposure. It does not mean resistant and does not independently specify a treatment regimen. Decisions also depend on the site, patient, contraindications, interactions and current guidance. This article explains mechanisms and terminology. The 2025 AWaRe classification concerns use policy, while the 2022 AWaRe book has subsequent updates; neither replaces an individual AST result.
Teaching example: from finding to conclusion
Teaching example: a panel detects NDM and a reader assumes aztreonam must be active. NDM generally does not hydrolyse this agent, but ESBLs, AmpC or other mechanisms can coexist.
Knowing one enzyme explains biochemistry rather than completing drug assessment. A validated result is needed for the isolate and, where relevant, the exact combination. A gene name is not a ready-made treatment recommendation.
Sources
Read next
Educational material from AMR Atlas. Does not replace clinical guidance or laboratory procedures.